Transforming
Anemia Management

Rockwell Medical is a biopharmaceutical company dedicated to improving patients' lives through effective treatment of iron deficiency and anemia.

Our Company Vision

Our vision is to establish a new standard of care for patients suffering with iron deficiency and iron deficiency anemia.

Iron deficiency anemia afflicts a subset of the two billion people worldwide who are nutritionally iron deficientREF. Approximately 10 million people are iron deficient in the United States, including 5 million who have iron deficiency anemia.

Learn more

Our Platform Technology

Ferric Pyrophosphate Citrate (FPC)

Our innovative therapeutic was developed to replace iron loss in patients with anemia in an entirely different way. Our unique and differentiated molecule, Ferric Pyrophosphate Citrate (FPC), provides a novel mechanism of action with a physiologic approach. FPC donates iron directly to circulating transferrin making it immediately bioavailable for critical body processes, which allows the body to use the iron in a physiologic manner.

Ferric Pyrophosphate Citrate in blood

FPC is introduced to the blood

FPC for iron deficiency

FPC donates iron directly and completely to transferrin – providing bioavailable iron for red blood cell production

avoids iron sequestration

FPC avoids iron sequestration by macrophages in liver and spleen

hemoglobin formation

Transferrin-bound iron immediately delivered to bone marrow for hemoglobin formation

FPC for maintaining hemoglobin

FPC delivers 100% bioavailable iron to maintain hemoglobin

Ferric Pyrophosphate Citrate in blood

FPC is introduced to the blood

arrow
FPC for iron deficiency

FPC donates iron directly and completely to transferrin – providing bioavailable iron for for red blood cell production

arrow
avoids iron sequestration

FPC avoids iron sequestration by macrophages in liver and spleen

arrow
hemoglobin formation

Transferrin-bound iron immediately delivered to bone marrow for hemoglobin formation

arrow
FPC for maintaining hemoglobin

FPC delivers the desired amount of iron maintenance over time

This novel approach to the treatment of iron deficiency and anemia has the potential for application in many disease states.

Investor Center

Access our investor center to learn about our strategies to deliver value for the patients we serve, the medical community, our employees and shareholders.

Access Now
investor center

Latest News

arrow left
arrow right

May 12, 2022

Rockwell Medical Submits Supplemental Data to FDA for IND Application for Phase 2 FPC Home Infusion Trial

WIXOM, Mich. , May 12, 2022 /PRNewswire/ --  Rockwell Medical , Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that it provided the U.S. Food and Drug Administration (FDA) with the supplemental data,

Read more

May 12, 2022

Rockwell Medical Announces 1-for-11 Reverse Stock Split

WIXOM, Mich. , May 12, 2022 /PRNewswire/ -- Rockwell Medical , Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that its Board of Directors has approved a 1-for-11 reverse split of the Company's issued

Read more

May 11, 2022

Rockwell Medical, Inc. to Report First Quarter 2022 Financial and Operating Results on May 16, 2022

WIXOM, Mich. , May 11, 2022 /PRNewswire/ -- Rockwell Medical , Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it will host a conference call

Read more

April 25, 2022

Rockwell Medical Announces Completion of Patient Enrollment Ahead of Schedule in Pivotal Phase 3 Clinical Trial of Triferic® in China

Trial with over 400 Patients Conducted by Partner Wanbang Pharmaceuticals , a Subsidiary of Fosun Pharma     Over 600,000 Patients receive Hemodialysis in China WIXOM, Mich. , April 25, 2022 /PRNewswire/ -- Rockwell Medical , Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to

Read more

April 20, 2022

Rockwell Medical to Present at Noblecon18 Investor Conference

WIXOM, Mich. , April 20, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (Nasdaq: RMTI) (" Rockwell Medical " or the "Company"), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients, today announced that the

Read more